CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Reacting to Islamic Apologists | GodLogic | Last Call Ep. 33 34 min · 24 Sep 2026 · Pints With Aquinas

Bond bombshell 22 min · 24 Sep 2026 · Unhedged

Do you have the correct time? 29 min · 24 Sep 2026 · BBC Inside Science

The High Schools Going All-In on AI 20 min · 24 Sep 2026 · The Journal.

Rosa Parks and the Montgomery Bus Boycott: Fighting to End Segregation 3h 6m · 24 Sep 2026 · Sleepy History

TNB Tech Minute: OpenAI Agents Attempt to Hack University and Government Websites 3 min · 24 Sep 2026 · WSJ Tech News Briefing

Report any issue

Source

Recorded11 Oct 2021

Publisherneurology.libsyn.com ↗

Handlerec:5447755

Show notes

In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in